The lawyers at Martin & Jones are investigating potential lawsuits on behalf of patients who suffered uncontrolled bleeding and even death as a result of taking the prescription blood thinner Xarelto (rivaroxaban).
Have you suffered injury from uncontrollable bleeding due to the drug Xarelto? Email our lawyers here or call toll-free 800.662.1234 for a free evaluation of your potential claim.
The majority of Xarelto cases have been filed in multidistrict litigation (MDL) before the Honorable Eldon Fallon in the Eastern District of Louisiana. An MDL is not a class action but rather individual plaintiff’s lawsuits consolidated with other individual plaintiff’s lawsuits from across the country to access information and conduct pre-trial discovery in a cost-effective, efficient manner. The Xarelto MDL was created in 2014, and there are now more than 15,600 cases that have been filed. The first bellwether or test case is set to begin on April 24, 2017 and the second is set on May 30, 2017. These bellwether cases will bring insight to the parties regarding the strength of the liability lawsuit against the manufacturers of Xarelto. The defendant companies are facing potential liability in the billions, based on settlements of Pradaxa, a similar blood thinning medication.
Xarelto was approved by the Federal Drug Administration (FDA) in July 2011 for use in preventing blood clots after knee and hip surgery and approved in November 2011 for use in reducing risk of stroke in patients with non-valvular atrial fibrillation. In November 2012, the FDA expanded the approval of Xarelto to include its use in treating and reducing the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). Deep vein thrombosis is a blood clot that forms in a vein deep in the body, most often occurring in the thigh or lower leg. Pulmonary embolism is a deep vein blood clot that breaks off and travels to an artery in the lungs.
Serious and sometimes fatal health problems such as uncontrollable, internal bleeding, blood clots, strokes, and kidney and liver damage have been reported by patients taking Xarelto. Uncontrolled gastrointestinal and epidural bleeding as well as brain hemorrhages have been reported. While uncontrolled bleeding is associated with many types of blood thinners like warfarin (Coumadin), most can be reversed immediately with treatment of high doses of vitamin K or frozen plasma, there is no such reversal treatment for Xarelto.
According to the FDA, Xarelto was “the first oral anti-clotting medication drug approved to treat and reduce the recurrence of blood clots since the approval of warfarin.” Xarelto is distributed in the United States by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. While warfarin users must have blood levels checked regularly by their doctors, the makers of Xarelto claim no such monitoring is required with Xarelto. In January 2014, the FDA issued a warning on the risk of bleeding with Xarelto advising physicians to “promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement.” This same warning included a statement about the inability to reduce the anticoagulant effect of Xarelto. The FDA issued a “boxed warning” in August 2013 that premature discontinuation of Xarelto could increase risk of thrombotic events.
If you or a family member has suffered uncontrolled bleeding that lead to injury or death, our attorneys can answer your questions about your legal rights. Our consultation is free and confidential. Call 800.662.1234 for your free consultation.